Alex Goldberg

MannKind Corp. (NASDAQ:MNKD) and Gilead Sciences Inc. (NASDAQ:GILD) Added to Equity Profile Report's NASDAQ Decliners Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 07/03/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding MannKind Corp. (NASDAQ:MNKD) and Gilead Sciences Inc. (NASDAQ:GILD).

MannKind Corp. (NASDAQ:MNKD) a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States closed down in its previous session (-4.98%) on 6,280,596 shares traded after MannKind Reached Financing Deal. MannKind Corp. (NASDAQ:MNKD) is currently down (-15.01%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about MannKind Corp. (NASDAQ:MNKD)

Gilead Sciences Inc. (NASDAQ:GILD) a biopharmaceutical company that discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia closed down in its previous session (-0.48%) on 2,795,651 shares traded. Gilead Sciences Inc. (NASDAQ:GILD) is currently down (-11.07%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Decliners Watch List.

Click Here to find out what other Investors are saying about Gilead Sciences Inc. (NASDAQ:GILD)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com